evolution of nir/pat within pfizer mid
TRANSCRIPT
![Page 1: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/1.jpg)
An Industry Perspective on the Potential for Emerging Process Analytical Technologies
Norman Winskill
Steve Hammond
Pfizer Global Manufacturing Services
![Page 2: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/2.jpg)
Agenda
History of PAT and vision for the future
Some specific, current PAT applications of interest
Possible implementation scenarios for these and other applications - shaping the future
Proposals to ensure that implementation proceeds as we ALL would like
“the win-win scenario”
![Page 3: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/3.jpg)
Evolution of NIR/PAT Within Pfizer
Mid ‘80s Control of fermentations, hazardous reactions, solvents, raw
materials, packaging materials, drug product process troubleshooting
Early ‘90s Dedicated group formed (‘90), libraries for APIs and RMs developed,
automated methods for sample presentation, some DP applications. Still largely NIR based
Late ‘90s Other techniques emerge (Raman, vision systems, acoustic, LIF etc.
Increasingly used in DP processes
![Page 4: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/4.jpg)
PAT Applications at DP Sites
RM Testing (warehouse based)
Packaging Components
Blending (at-line or on-line)
Drying
Tableting (potency and CU)
Encapsulation (potency and CU)
Tablet Coating (coating thickness)
Packaged product
Equipment cleaning (on line monitoring of CIP)
Equipment cleaning (surface monitoring)
Note - Less than 15% of applications at US sites
![Page 5: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/5.jpg)
What Does the Future Hold?
Significant increase in number of applications
Broadening of type of analysis e.g. mid-IR, Raman, LIF, acoustic, vision
Availability of “off the shelf” solutions, including analyzers offered as options by equipment vendors
Integration of applications. Used for “Continuous Quality Verification” as opposed to control of discrete unit operations
![Page 6: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/6.jpg)
Shift the Manufacturing Paradigm
![Page 7: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/7.jpg)
Changing the Manufacturing Paradigm - Challenges
Considerable progress in some areas chemometrics, fiber optics, “industrialization” of some
instruments (e.g. NIR)
Opportunities still exist in other areas smaller, faster, cheaper instruments (e.g. Raman) sample interfaces
Real or perceived regulatory hurdles may effect the way PAT is implemented
Technical
Regulatory
![Page 8: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/8.jpg)
On-Line analysis of blending
Driven by safety issues with new potent API’s
Uses battery power and radio communication
Small fast diode array instrument
Mounted on the moving blender
Controlled outside of containment area
Results appear outside of containment area
![Page 9: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/9.jpg)
Layout of Containment Blending Room
Corridor
Blender Room
2nd Containment Room
1st Containment Room
Store Room
PC with RF Link
Blender with NIR & RF Link
~25 feet
![Page 10: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/10.jpg)
On- line NIR bin blender
Reading Head
NIR Instrument
Battery RF Module
Fibre optic
![Page 11: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/11.jpg)
Corona Sensor Head
Light
Lid of blender & window
Focal Point just inside bin
30mm
Fibre Optic Collector
Fibre Optic to Detector
Contributing sample weight is ~300mg
![Page 12: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/12.jpg)
Saccharin Specific Absorption
Saccharin
Avicel
LactoseSaccharin increasing absorbance with blending
![Page 13: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/13.jpg)
Absorbance of Blend Components (Step 1)
-12
-10
-8
-6
-4
-2
0
2
4
0 6 12 18 24 30 36 42 48 54 60Sample Points (~12 seconds each)
Abso
rban
ce
Saccharin 1630nm Lactose 1450nm Avicel 1425nm
![Page 14: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/14.jpg)
Blend Uniformity All ingredients(Step 1)
0
0.5
1
1.5
2
2.5
3
3.5
0 6 12 18 24 30 36 42 48 54 60Sample Point (~12 seconds each)
8 Po
int V
aria
nce
Saccharin 1630nm Avicel 1425nm Lactose 1450nm
![Page 15: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/15.jpg)
Magnesium Stearate Uniformity (Step 2)
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0 6 12 18 24 30 36 42 48 54 60Sample Point (~12 seconds each)
8 Po
int V
aria
nce
Mag Stearate 1390nm
![Page 16: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/16.jpg)
On-line blending - benefits No operator contact
No sampling errors - no thief
real-time information
Multi-ingredient uniformity
Process understanding
Process finger- printing for scale up
Right first time
Fast release of the blend - reduced cycle times
![Page 17: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/17.jpg)
Tablet analysis by NIR transmission
Started at-line with plant operators analysing 200 -400 cores per lot
With containment issues needs to be non attended
Development of a fully automated test station sited at the press
NIR chemical analysis - weight thickness hardness by normal module
Integrated into one unit.
![Page 18: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/18.jpg)
NIR in Production
![Page 19: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/19.jpg)
Fibre Optic Probe
InGaAs (Indium Gallium Arsenide) Detector
Fibre Bundle
Removable Probe Tip
Tablet Holder
Tablet
Light Path
NIR Tablet Transmission Device
![Page 20: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/20.jpg)
Tablet core potency - blend segregation in the bin
![Page 21: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/21.jpg)
Automated tablet analysis
NIRIdentityPotencyUniformityBruker
Weight ThicknessHardnessDr S Pharmatron
![Page 22: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/22.jpg)
Absorbance of active tablets Vs placebos
1.261.281.301.321.341.361.38
-0.5
0.0
0.5
1.0
1.5
2.0
Abso
rban
ce U
nits
![Page 23: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/23.jpg)
NIR transmission Vs conc in tablets 0.1% - 2.0%
![Page 24: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/24.jpg)
Microscopic View of Dosage Form
Blend Tablet
![Page 25: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/25.jpg)
NIR Microscopy mapping process
Area which individualspectra are collected
from.
SampleArea
Using SpectralInformation
Component 3
Component 2Component 1
CHEMICAL IMAGE MAP
WhereBlue = Component 1Red = Component 2Green = Component 3
![Page 26: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/26.jpg)
Distribution of Lubricant in BlendSpectra obtained every 15m, 0.6mm X 0.6mm area
Good Flow BlendBad Flow Blend
![Page 27: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/27.jpg)
Diluent Binder Active Disintegrant Lubricant
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
PixelsPi
xels
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Pixels
Pixe
ls
20 40 60 80 100 120 140
20
40
60
80
100
120
140
Maps of sticking and non-sticking tablets
Non sticking
Sticking
![Page 28: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/28.jpg)
MatrixNIR - Spectral Dimensions
![Page 29: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/29.jpg)
Changing the Manufacturing Paradigm - Challenges
Considerable progress in some areas chemometrics, fiber optics, “industrialization” of some
instruments (e.g. NIR)
Opportunities still exist in other areas smaller, faster, cheaper instruments (e.g. Raman) sample interfaces
Real or perceived regulatory hurdles may effect the way PAT is implemented
Technical
Regulatory
![Page 30: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/30.jpg)
The “Don’t Use” Scenario What:
Modern PAT methods not used/developed during product development so not used for routine process control
Why: Fear of regulatory delays Wasteful of resources to duplicate method development
-“current methods work OK” Concern of “raising the bar” unnecessarily: information
generated for one process may be expected from all
Issues: Loss of benefit of PAT - improved process information and
control
![Page 31: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/31.jpg)
Example of “Don’t Use” - Antifungal Polymorph Conformation
Powder XRD
Established technique
Not common in IPC/QO labs
Did not exist at site of manufacture
Samples sent to another site 3,500 miles away for release (LT 1 week plus)
NIR
New technique (for polymorph)
Common in IPC/QO labs
Existed at site of manufacture
All assays could be done on site (LT minutes if necessary)
Method A Method B
![Page 32: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/32.jpg)
The “Don’t Tell” Scenario What:
PAT methods not registered but used in parallel with registered (conventional) methods to gain greater process insight and control
Why: Concern over delays in regulatory approval Concern that data may be interpreted inappropriately by
regulators. More data will lead to more deviations from “norms” - need to be able to determine which are relevant and which are not
Issues: Duplication, inefficiency, environment of “mistrust”
![Page 33: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/33.jpg)
Control of Antibiotic FermentationParameter Registered method Advanced Benefit
Antibioticconcentration
HPLC after extraction.time to result 2 hours
NIRtime to result 15 mins
Efficient analysis providesresource for more data pointsKinetic production curves
Cell growth Differential centrifugationtime to result 12 hours
NIRtime to result 15 mins
Kinetic growth curves linked toother measurement i.e. productionrates - process understanding
Residual Fat Solvent extractiontime to result 4 hours
At-line NIRtime to result 15 minsOn-line NIRcontinuous
x4 more data points, and almost“real time” values improvescomputer trending thus control ofresidual level
Respiration rate Mass spec. of off-gastime to result continuous
Allows computer control by realtime trendingAllows balancing of residualnutrient levels to cell state andactivity
Dissolved oxygen Redox probetime to result continuous
Allows computer control by realtime trendingAllows balancing of residualnutrient levels to cell state andactivity
![Page 34: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/34.jpg)
Benefits of Improved Control
Conventional methods give product which is fit for intended use, but…
Advanced control gives better batch to batch consistency better quality (less impurities) fewer reworks/rejects better productivity lower cost improved process understanding faster response times
![Page 35: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/35.jpg)
The “Win - Win” Scenario What:
Modern PAT methods used to gain greater understanding of processes during development, are registered and used as in-process control (and release?) methods
PAT methods accepted as alternatives to traditional lab based methods - but not required
Why: Methodology understood and accepted by regulators and
industry alike
Issues: This is where we should all want to get to. Making progress,
but we are not there yet……….
![Page 36: Evolution of NIR/PAT Within Pfizer Mid](https://reader031.vdocuments.net/reader031/viewer/2022030323/58a2fb761a28ab6a748b7013/html5/thumbnails/36.jpg)
How can we create a “Win-Win” Environment?
Sponsor joint forums to promote discussion and enhance understanding of the issues and opportunities offered by PAT
Develop an effective process for the evaluation of new PATs
Develop appropriate guidelines for the development, validation and implementation of new PATs
lab based extraction/chromatography rules don’t apply participate in “dummy run” submissions
Ensure consistent approach to PAT by Review and Inspection
Dealing with the real or perceived regulatory hurdles: